Anzeige
Mehr »
Login
Samstag, 18.01.2020 Börsentäglich über 12.000 News von 621 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12DWY ISIN: CA4576371062 Ticker-Symbol: MWG2 
Frankfurt
17.01.20
17:49 Uhr
0,196 Euro
+0,033
+19,90 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INMED PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
INMED PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,198
0,211
11:04
0,194
0,213
17.01.

Aktuelle News zur INMED PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
INMED PHARMACEUTICALS Aktie jetzt für 4€ handeln
DoInMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress-
MiInMed Pharmaceuticals (IMLFF) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow2
MiCannabis-Afrika-Serie Teil 1: Riesenpotential in Afrika für Bewohner und Firmen
11.01.InMed Announces Election of Directors-
11.01.Inmed Pharmaceuticals Inc: Inmed shareholders elect five directors at AGM1
08.01.InMed Pharmaceuticals to Present at the Biotech Showcase Conference-
09.12.19Inmed Pharmaceuticals Inc: Inmed receives regulatory nod for INM-755 trial-
09.12.19InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa1
18.11.19Inmed Pharmaceuticals Inc: Inmed files INM-755 clinical trial application-
18.11.19Edison Investment Research Limited: Edison issues update on InMed Pharmaceuticals199LONDON, UK / ACCESSWIRE / November 18, 2019 / InMed Pharmaceuticals (TSX:IN) recently announced that it filed a Clinical Trial Application in the Netherlands for INM-755, which is being developed for...
► Artikel lesen
18.11.19InMed Pharmaceuticals - CTA filed on schedule148InMed Pharmaceuticals recently announced that it filed a Clinical Trial Application (CTA) in the Netherlands for INM-755, which is being developed for epidermolysis bullosa (EB). Approval of the CTA...
► Artikel lesen
11.11.19InMed Pharmaceuticals to Present at the Cowen Conference1
08.11.19Inmed Pharmaceuticals Inc: Inmed spends $2.33-million on R&D in Q1 2020-
08.11.19InMed Pharmaceuticals reports Q1 results2
08.11.19InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update-
05.11.19Inmed Pharmaceuticals Inc: Inmed applies for INM-755 clinical trial-
05.11.19InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial-
04.11.19InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019-
18.10.19InMed Pharmaceuticals to Present at the BIO Investor Forum-
02.10.19InMed Pharmaceuticals Is A Small Underfunded Medical Marijuana Company That Has A Potentially Revolutionary Product1
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1